Chemistry Reference
In-Depth Information
M. Zhang, D. Zhu, M. H. Norman and N. R. Gavva, J. Pharmacol. Exp.
Ther., 2008, 326, 218.
68. Adapted in part with permission from J. Med. Chem., 2008, 51, 2744.
69. A. A. Romanovsky, Am. J. Physiol. Regul. Integr. Comp. Physiol., 2007,
292, R37.
70. P. S. Burton, R. A. Conradi, N. F. Ho, A. R. Hilgers and R. Borchardt,
J. Pharm. Sci., 1996, 85, 1336.
71. S. A. Hitchcock and L. D. Pennington, J. Med. Chem., 2006, 49, 7559.
72. C. Hansch, J. P. Bjorkroth and A. Leo, J. Pharm. Sci., 1987, 76, 663.
73. W. R. Glave and C. J. Hansch, J. Pharm. Sci., 1972, 61, 589.
74. K. M. Mahar Doan, J. E. Humphreys, L. O. Webster, S. A. Wring, L. J.
Shampine, C. J. Serabjit-Singh, K. K. Adkison and J. W. Polli, J. Phar-
macol. Exp. Ther., 2002, 303, 1029.
75. S. J. Cho, X. Sun and W. Harte, J. Comput. Aided Mol. Des., 2006, 20, 249.
76. X. Wang, P. P. Chakrabarti, V. I. Ognyanov, L. H. Pettus, R. Tamir,
H. Tan, P. Tang, J. J. S. Treanor, N. R. Gavva and M. H. Norman, Bioorg.
Med. Chem. Lett., 2007, 17, 6539.
77. CNS penetration was evaluated by measuring brain-to-plasma ratios.
Plasma and brains were collected 30 min after dosing and total con-
centration of compound was determined by HPLC. For the purpose of this
study we measured compound concentrations in non-perfused whole-brain
samples. Taking into account the residual concentration of drug present as
a consequence of brain capillary blood volume, we considered compounds
having a brain-to-plasma ratio of less than or equal to 0.1 as peripherally
restricted.
78. M. J. Caterina, Pain, 2008, 136,3.
79. S. S. Ayoub, J. C. Hunter and D. L. Simmons, Pharmacol. Rev., 2009, 61,
225.
80. A. A. Romanovsky, M. C. Almeida, A. Garami, A. A. Steiner, M. H.
Norman, S. F. Morrison, K. Nakamura, J. J. Burmeister and T. B. Nucci,
Pharmacol. Rev., 2009, 61, 228.
Search WWH ::
Custom Search